Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0005940 (bone disease)
 7,459 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The part played by calcium in genesis of essential hypertension may be suspected. Yet, the whole of epidemiological research as well in the animal as in man is still not very convincing. The objective of such a research has been to appreciate the calcium intestinal absorption before and after nicardipine treatment in 11 subjects (5 M/6 F) aged between 32 and 82. The group is made up of 7 hypertensive patients (2 M/5 F) and 4 normotensive ones (3 M/1 F). Subjects showing bone disease, kidney insufficiency and stone in kidneys or under such a treatment as to interfere with calcium metabolism had been excluded. Dosage of calcium and phosphate, Na, K, aldosterone, in blood and urine and PTH and PRA in blood had been effectuated. Estimation of true calcium absorption has been made by double isotope deconvolution method. Blood pressure has been measured by semi-ambulatory monitoring method. Similar evaluation has been made after four weeks treatment (60 mg of nicardipine a day). Without any treatment, normotensive subjects have a lower intestinal absorption coefficient than the hypertensive ones, which is normal (non significative statistical results: NS). Under nicardipine, hypertensive patients seem to get lower intestinal absorption (NS); other clinical, biological parameters show no change, except a rise of apoprotein A after nicardipine treatment (P less than or equal to 0.05). So, the intestinal absorption of calcium would become higher in hypertensive subjects and diminished by calcium antagonist treatment.
 ...
PMID:[Calcium intestinal absorption in normotensive and essential hypertensive subjects before and after nicardipine]. 251 Jun 63

Ten patients with renal failure not on dialysis were subjected to our study to evaluate the effect of 1 alpha (OH)D3 on calcium metabolism and its influence on renal function. The results suggest the possibility that 1 alpha (OH)D3 might be effective in bone disease due to secondary hyperparathyroidism. On the other hand, 1 alpha (OH)D3 depressed creatinine clearance without any increase of Ca, Ca x P product or PRA. 1 alpha (OH)D3 is to be prescribed to patients not on dialysis only with careful attention to the dosage and the duration, and frequent observation of renal function is necessary.
 ...
PMID:Deterioration of renal function in non-dialytic uraemics caused by 1 alpha (OH)D3 which was not attributable to hypercalcaemia. 724 99